Drug profile · INN
simvastatin
APO-SIMVASTATIN
simvastatin (APO-SIMVASTATIN) is a hmg-coa reductase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — simvastatin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 14
- Data quality
- 0.89
Quick answer
simvastatin (APO-SIMVASTATIN) is a hmg-coa reductase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
HMG-CoA reductase inhibitor
Primary target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11197844
Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
granted -
US 10813909
Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
granted -
US 10793884
Methods and materials for making simvastatin and related compounds
granted -
US 9970037
Methods and materials for making simvastatin and related compounds
granted -
US 8951754
Methods and materials for making simvastatin and related compounds
granted -
US 8211664
Methods and materials for making simvastatin and related compounds
granted
Frequently asked questions
What is simvastatin?
simvastatin (APO-SIMVASTATIN) is a hmg-coa reductase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for simvastatin?
APO-SIMVASTATIN is a marketed brand name for simvastatin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of simvastatin?
simvastatin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.